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Anemia: The Point of Convergence or
Divergence for Kidney Disease and Heart Failure?
Amir Kazory, MD, Edward A. Ross, MD
Gainesville, Florida
Cardiorenal anemia syndrome refers to the simultaneous presence of anemia, heart failure (HF), and chronic
kidney disease (CKD) that forms a pathologic triangle with an adverse impact on morbidity and mortality. The
reciprocal relationships among these 3 components have been the subject of a number of trials with inconsis-
tent and sometimes paradoxic results. In this paper, the pathophysiologic concepts underlying interactions
among these 3 conditions are discussed. Then, the similarities and dissimilarities of the relationships between
anemia and either HF or CKD are considered; explanations are provided for differences in the results of the cur-
rently available studies. Erythropoietin-stimulating agent protocols are usually based on the results of studies
designed for the CKD population, and upper hemoglobin target levels are chosen to avoid cardiovascular compli-
cations. It is not yet clear whether those renal guidelines are optimal for patients with HF, especially because
those patients may have reversible components of kidney dysfunction, both HF and renal parameters improving
with anemia correction. We review these issues and suggest a pragmatic approach to the care of patients with
HF until such time that controlled trials establish definitive anemia treatment goals that are dynamic and dis-
ease specific, rather than those that adopt a more simplistic hemoglobin-specific approach. (J Am Coll Cardiol
2009;53:639–47) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.10.046t
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ghronic kidney disease (CKD) and heart failure (HF) share
number of causes (e.g., hypertension), features (e.g.,
alnutrition), and risk factors (e.g., older age). It is not then
urprising to see these 2 pathologic situations coexist in a
arge number of patients. CKD is highly prevalent in
atients with HF, with a substantial number of them even
rogressing to end-stage renal disease (ESRD) (1). In a
eta-analysis of 16 studies, Smith et al. (2) found that 63%
f the 80,098 patients with HF concomitantly had some
egree of impaired renal function, and 29% presented with
evere CKD. This is of great clinical relevance because it is
ell known that renal dysfunction in patients with HF is
ssociated with an increased risk of adverse outcomes (1,2).
n a study by Hillege et al. (3) on 1,906 patients with HF,
mpaired renal function was found to be an even stronger
redictor of mortality than ejection fraction (EF) or New
ork Heart Association (NYHA) functional class. The
eciprocal relationship also holds true and has been the
ubject of much interest: cardiovascular disease is a very
ommon comorbidity in patients with CKD or ESRD and
s the leading cause of mortality in this patient population.
ndeed, HF is the key component of cardiovascular mor-
idity and mortality across the entire spectrum of CKD with
2-year cumulative probability of 39.5% (4). In a study of
rom the Division of Nephrology, Hypertension, and Transplantation, University ofs
lorida, Gainesville, Florida.
Manuscript received September 16, 2008; accepted October 22, 2008.he Medicare population, Foley et al. (5) found that 39.9%
f patients with CKD had HF on initial presentation, and
nother 30.7% developed it over the next year. Not only is
F the most common type of cardiovascular disease seen in
atients new to ESRD, but according to the U.S. Renal
ata System 2007 annual data report, approximately two-
hirds of incident dialysis patients develop HF within 3
ears (4).
nemia in HF
he prevalence of anemia in the HF population has been
ubject to very wide variations based on its definition and
he study population. Currently, there is no specific hemo-
lobin concentration that has universally been accepted as a
linically relevant definition for anemia in HF. Some studies
ave applied the World Health Organization classification
n their analyses (6,7), whereas others have chosen a
emoglobin level of 12 or 12.5 g/dl (8,9). Overall, the
ajority of studies indicate that the prevalence of anemia in
he HF population is 20%; many have reported it as high
s 50% (10). In the OPTIMIZE-HF (Organized Program
o Initiate Lifesaving Treatment in Hospitalized Patients
ith Heart Failure) registry that contained information on
8,612 patients hospitalized for HF, 51.2% of the cohort
ad hemoglobin levels of 12.1 g/dl and 25% were mod-
rately to severely anemic (hemoglobin levels of 5 to 10.7
/dl) (11). In addition, the prevalence of anemia increases
ignificantly with disease severity. Although it can be very
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advanced HF, fewer patients
with mild to moderate or new-
onset HF are anemic.
Most studies have found that
anemia is associated with an in-
creased risk of adverse outcomes
in the HF population (10). In the
OPTIMIZE-HF registry, a lower
hemoglobin level was indepen-
dently associated with higher all-
cause and cardiovascular mortal-
ity and morbidity in hospitalized
patients with HF (11). Similarly,
Tang et al. (12) recently reported
that even in the ambulatory set-
ting, the presence of persistent
anemia conferred poor survival in
these patients. In this study, for
each 1-g/dl decrease in the he-
oglobin level, there was a 20% increase in the multivariate
djusted risk of death. Many investigations, however, are
ifficult to compare because of diverse ranges of hemoglobin
alues and possible confounding effects of other aspects of
ardiac disease (e.g., degree of left ventricular [LV] systolic
ysfunction).
Multiple etiologies have been proposed for anemia in the
etting of HF (Table 1). These include occult gastrointes-
inal bleeding owing to concomitant use of aspirin, hemodi-
ution, inhibition of either erythropoietin (EPO) synthesis
i.e., possibly secondary to use of angiotensin-converting
nhibitors or angiotensin receptor blockers), and nutritional
ron deficiencies caused by anorexia (13–15). However, the
ause that may provide the most insight into the pathophys-
ology is unresponsiveness to EPO. Indeed, compared with
atients with ESRD who are functionally anephric and have
bsolute EPO deficiency, patients with congestive heart
ailure (CHF) typically have elevated plasma EPO levels
16,17). The loss of EPO sensitivity is thought to be due to
hronic inflammation, as evidenced by increases in a mul-
itude of inflammatory cytokines. Further complicating
nalysis of the literature is the finding that erythropoiesis-
timulating agent (ESA)-induced improvement in anemia
an be associated with improvements in CHF and reduction
Abbreviations
and Acronyms
CHF  congestive heart
failure
CKD  chronic kidney
disease
EF  ejection fraction
EPO  erythropoietin
ESA  erythropoiesis-
stimulating agent
ESRD  end-stage renal
disease
GFR  glomerular filtration
rate
HF  heart failure
LV  left ventricular
NYHA  New York Heart
Association
auses of Anemia in Heart Failure
Table 1 Causes of Anemia in Heart Failure
Relative erythropoietin deficiency
Resistance to erythropoietin
Nutrition deficiencies (e.g., iron, folate, and vitamin B12)
Malabsorption secondary to edema of the gastrointestinal mucosa
Limited availability of iron for erythropoiesis
Elevated levels of inflammatory cytokines
Hemodilution
Drugs (e.g., ACE-I, ARB, warfarin, and aspirin)dCE-I  angiotensin-converting enzyme inhibitor; ARB  angiotensin-II receptor blocker.n cytokine levels (18). The syndrome of inflammation,
PO resistance, and anemia could hypothetically identify
atients with high-risk CHF and confound therapeutic
rials: 1) patients would need to be randomized based on
arkers of inflammation; 2) analyses would have to account
or the ESA dose needed to achieve a target hemoglobin
evel; and 3) there might be very large doses of ESA (and
ron) necessary in protocols with high hemoglobin level end
oints. The latter concern is at the crux of many controver-
ies in this field. Do adverse outcomes in therapeutic trials
ccur because of targets of high (i.e., normal or near-
ormal) hemoglobin levels or are the complications due to
he increased doses of ESA (and iron) needed to achieve
hat degree of erythropoiesis in the setting of systemic
nflammation? This issue has profound implications in
erms of ESA usage for a variety of medical illnesses, as
lready manifested by recent hemoglobin-oriented Food
nd Drug Administration-mandated changes in ESA label-
ng. The question of drug toxicity (rather than the hemo-
lobin level per se) does have a basis in the literature. ESAs
re known to have adverse effects, including those owing to
nhibition of the nitric oxide pathway, worsening hyperten-
ion, and blood viscosity. It is also noteworthy that higher
oses of EPO have been shown to diminish nitric oxide
roduction and release in certain circumstances (e.g., high
lood pressure and uremic environments), leading to ad-
erse vascular effects (19). Iron therapy (which, alone, is
eported to alleviate anemia and improve cardiac function in
ome studies of patients with CHF [20–23]) increases
xidative stress. Unfortunately, to date no large prospective
tudy has been specifically designed to investigate this topic.
andomizing patients to receive either blood transfusions or
SA/iron could be a strategy to clarify the role of ESA (and
ron) as independent risks; however, there have been no
arge trials so far in this regard. As described later, resolving
he central question of whether adverse events are due to the
emoglobin level or drug effect could explain why many
bservational (i.e., epidemiologic) investigations have dem-
nstrated better outcomes with higher hemoglobin values,
ven though at those same levels some therapeutic trials
howed worsened end points. Unfortunately, it is not known
hether the results of this and other large, multicenter,
andomized, controlled trials of ESAs in CKD populations
an be applied to patients with CHF. In this regard,
iscussed in the following section are attributes of patients
ith anemia and HF that are either similar to or different
rom those with renal disease (points of “convergence” or
divergence,” respectively).
nemia in CKD
lthough it is a relatively recent focus in the cardiology
iterature, anemia has been a long-recognized, common, and
ell-studied complication of CKD. Anemia occurs early in
he course of the disease and worsens as kidney function
eclines. In a multicenter survey on 5,222 patients with
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February 24, 2009:639–47 Anemia in CKD and HFKD, McClellan et al. (24) showed that anemia (hemoglo-
in level 12 g/dl) was present in 47.7% of the study
opulation. The prevalence of anemia was strongly associ-
ted with declining glomerular filtration rate (GFR); the
ercentage of patients with hemoglobin levels 12 g/dl
ncreased from 26.7% to 75.5% when GFR decreased from
60 to 15 ml/min/1.73 m2.
Although decreased EPO production is largely responsi-
le for development of anemia in patients with advanced
KD, several other etiologies have also been considered
Table 2). Decreased red blood cell life span owing to the
resence of uremic toxins, chronic blood loss secondary to
latelet dysfunction, nutritional (e.g., folate) deficiencies,
ron deficiency (functional or absolute), and elevated inflam-
atory cytokine levels that suppress the bone marrow are
mong these factors (25) (Fig. 1).
Anemia is recognized as an independent risk factor for
rogression of renal disease in patients with CKD (26), and
issue hypoxia is one of the proposed mechanisms. Further-
ore, in a study of 6,541 patients with CKD, anemia was
ound to be an independent predictive factor for reaching
SRD and needing replacement therapy (27). Anemia has
lso been considered a risk multiplier in the presence of
ardiovascular disease, the common comorbidity of CKD. In a
etrospective study on 88,657 patients with elevated serum
reatinine levels, Walker et al. (28) found that patients with
nemia had an increased risk for progression of CKD to
ialysis as well as a higher (2 to 5 times) risk for myocardial
nfarction. Interestingly, the risk for hospitalization with HF
eclined regularly with increasing hemoglobin levels.
nemia: The Point of Convergence
n 2004, the National Heart, Lung, and Blood Institute
onvened a working group of investigators to examine the
vailable data concerning interactions between the cardio-
ascular system and kidneys and to develop recommenda-
ions for future studies (29). The definition of the cardio-
enal syndrome as a “state in which therapy to relieve
ongestive HF symptoms is limited by further worsening
idney function” arose from the work carried out by that
auses of Anemia in Chronic Kidney Disease
Table 2 Causes of Anemia in Chronic Kidney Disease
Relative erythropoietin deficiency
Resistance to erythropoietin
Reduced expression of erythropoietin receptors
Perturbed erythropoietin signal transduction
Impaired proliferation of erythroid precursor cells
Limited availability of iron for erythropoiesis
Nutrition deficiencies (e.g., iron, folate, and vitamin B12)
Elevated levels of inflammatory cytokines
Platelet dysfunction resulting in blood loss (e.g., occult gastrointestinal bleeding)
Retained blood in extracorporeal circuits for patients with ESRD
Hyperparathyroidism
Drugs (e.g., ACE-I, ARB, and aspirin)tSRD  end-stage renal disease; other abbreviations as in Table 1.roup (30). Since then, the definition of the cardiorenal
yndrome has been expanded to stress the bidirectional
ature of the relationship between the kidney and the heart:
“pathophysiological disorder in which acute or chronic
ysfunction of one organ may induce acute or chronic
ysfunction in the other” (30). The biologic mediators for
his clinical interaction are thought to be hyperactivity of
he sympathetic nervous system, the renin-angiotensin-
ldosterone system, imbalance of nitric oxide and reactive
xygen species, and the chronic inflammatory state (19).
hese mediators, also called “cardiorenal connectors,” display
utual interactions and induce positive feedback loops at many
oints (31). The clinically relevant concept of the cardiorenal
yndrome is that renal and cardiac dysfunction mutually
mplify progressive failure of both systems; CKD can cause or
orsen HF, and HF also can cause or worsen CKD.
Anemia, a common feature of both CKD and HF, seems
o be another piece of this puzzle. It can cause or worsen
KD and HF and be the consequence of either of these 2
onditions as well. This has prompted some authors to
xpand this concept with special emphasis on the role of
nemia in a vicious cycle; the term “cardiorenal anemia
yndrome” has recently emerged and is increasingly used to
escribe this association (32). It implies that there is a
ause-and-effect relationship between any 2 of these patho-
ogic conditions and that anemia can lead to the develop-
ent of CKD and HF through the aforementioned patho-
hysiologic pathways. For example, in a study on more than
million Medicare elderly patients, Herzog et al. (33) found
hat CKD, HF, and anemia are additive in increasing
ortality and the risk of developing ESRD.
Anemia, CKD, and HF thus form a pathologic triangle,
utually amplifying their impacts on morbidity and mor-
ality. These relationships highlight the pathophysiologic
asis whereby anemia may not merely be a “marker” of more
evere disease in CKD or HF but rather a “mediator” for
evelopment of the diseases. As described later, this concept
s of paramount importance in establishing the targets of
nemia correction. Some patients with anemia have concur-
ent but unrelated parenchymal cardiac and renal diseases;
or these patients, it would be reasonable to use the
ell-established national guidelines for correction of anemia
n the CKD population. Other individuals, however, may
ave cardiac disease that plays a primary role in worsening
enal dysfunction. It is the latter subset of patients that is
ost intriguing because of the theoretical possibility that
melioration of anemia would lead, in turn, to improvement
n HF and then better renal function. Indeed, the results of
number of studies are consistent with this hypothesis
34,35). In a study on 179 patients with moderate to severe
F and mild to moderate CKD, Silverberg et al. (35)
eported that correction of anemia through administration
f EPO and iron was followed by improvement in the LV
ystolic function as well as blocking the progression of
KD. Other investigations have shown similar demonstra-
ions of either stabilization or improvement in renal func-
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Anemia in CKD and HF February 24, 2009:639–47ion after the correction of anemia; however, most have
tudied small numbers of patients and used different hemo-
lobin goals (36–38). We believe that it is critically impor-
ant to be able to identify the group of patients that will have
hemodynamic-mediated improvement in renal function.
hey might theoretically fare better with cardiac disease-
pecific hemoglobin targets, which could be quite different
han guidelines for those individuals with primary renal
isease.
Relative EPO deficiency and resistance to EPO are
lso 2 major pathologic phenomena that link the anemia
f CKD with that of HF. Although endogenous EPO
evels are higher in patients with CKD compared with
hose in healthy individuals, they are inappropriately low
or the degree of anemia (relative EPO deficiency)
39,40). Anemia persists in patients with CKD despite
he average EPO levels being approximately 5 times
Figure 1 Proposed Pathophysiology Underlying Anemia and Its
in Patients With Both CHF and Renal Dysfunction (Th
CHF  congestive heart failure; ESA  erythropoiesis-stimulating agent;  and igher than those in healthy individuals (EPO resistance) r41). As previously noted, similar to the CKD popula-
ion, serum EPO levels have been found to be high in
atients with HF (16) but disproportionately low for the
egree of anemia (17). Conversely, it has recently been
ypothesized that high EPO levels could be beneficial by
ampening the cardiorenal connectors (19,42) through
xtrahematopoietic effects in addition to the traditional
enefits from anemia correction.
nemia: The Point of Divergence
s mentioned earlier, in addition to the cause-and-effect
elationship, the term cardiorenal anemia syndrome im-
lies that common pathophysiologic pathways drive the
nterplay of the 3 components of the syndrome. One
ight anticipate that modifications (i.e., improvement or
eterioration) of a single component of this triad would
ction
diorenal Syndrome)
itive and negative effects, respectively.Corre
e Car
 posesult in changes in a similar direction in the other two.
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February 24, 2009:639–47 Anemia in CKD and HFor instance, as HF worsens, the GFR would decline and
nemia would worsen, with a consequent increase in
ortality. However, there can be unanticipated interac-
ions between these disease states, such as the impact of
nemia correction in patients with CKD or HF. It seems
hat, for reasons not yet well known and dependent on
he degree of anemia correction, there may be different,
r even opposite, effects on the clinical outcomes of
atients with CKD compared with those of patients with
F. For example, anemia has been recognized as an
ndependent risk factor for progression of kidney disease
27) and has been shown to portend a poor prognosis in
atients with CKD (43); however, complete normaliza-
ion of the hemoglobin levels has not been associated
ith improvement in outcomes in this population. In-
eed, recent studies have consistently found that correc-
ion of anemia in patients with CKD actually increases
he risk of adverse outcomes, although it might improve
ardiac function and structure (44). The CHOIR (Cor-
ection of Hemoglobin and Outcomes in Renal Insuffi-
iency) study evaluated the effects of achieving relatively
igh hemoglobin levels (13.5 g/dl) compared with lower
emoglobin levels (11.3 g/dl) on cardiovascular outcomes
n a CKD population. This study was prematurely halted
ecause of a surprisingly higher rate of adverse events in
he high hemoglobin group (45). A similar randomized,
ontrolled trial (CREATE [Cardiovascular Risk Reduc-
ion by Early Anemia Treatment with Epoetin Beta]
tudy) evaluated the impact of complete compared with
artial correction of hemoglobin levels in a CKD popu-
ation (46). Complete correction of anemia again failed to
emonstrate any improvement in cardiovascular events.
nother study of patients with cardiac disease (HF or
schemic heart disease) on hemodialysis was previously
alted after 29 months because of a surprisingly increased
ate of adverse outcomes in the group with a normal
ematocrit therapeutic goal (47). Thus, the guidelines for
he management of anemia in patients with CKD have
ecently been updated to reflect the practical conse-
uences of the aforementioned clinical trials (48). Nota-
ly, however, all of these trials were open label, not all
ctually achieved the targeted hemoglobin levels, and
here was a concern over potentially confounding adverse
ffects of intravenous iron dosing needed for erythropoi-
sis. The currently ongoing TREAT (Trial to Reduce
ardiovascular Events With Aranesp Therapy) is a large,
andomized, placebo-controlled, double-blind study that
ims to evaluate the effect of increasing hemoglobin levels
to 13 g/dl) on cardiovascular end points in patients with
nemia and CKD (and diabetes) (49). These conflicting
ndings (in observational vs. therapeutic trials) again
ighlight our lack of understanding of the pathophysiol-
gy of erythropoiesis in inflammatory conditions, adverse
ffects from the hemoglobin level, or the doses of
harmaceuticals used to reach that goal. Importantly, a
ecent secondary analysis of the CHOIR study suggested bhat the high cardiovascular event rates were limited to
hose patients receiving large ESA doses and having
uboptimal hemoglobin responses. Individuals who
chieved higher hemoglobin levels with relatively low
harmaceutical doses did not have the vascular compli-
ations (50).
In marked contrast to these negative or neutral studies in
KD populations, a number of studies of patients with HF
ave reported that correction of anemia to normal or
ear-normal levels is associated with beneficial impact on
ardiovascular outcomes. Silverberg et al. (32) were the first
o evaluate the role of anemia correction in the HF
opulation. In a randomized, open label study on 32
atients with HF, they found that an increase in hemoglo-
in level was followed by improvement in NYHA functional
lass and LVEF. Palazzuoli et al. (51) in a randomized,
ouble blind, placebo-controlled study of 40 patients with
oderate to severe HF found that correction of anemia was
ssociated with improvement in NYHA functional class,
-type natriuretic peptide levels, and even renal function.
he apparent discrepancy between the findings of studies on
ggressive anemia correction in patients with CKD as
ompared with those in patients with HF has continued
ver time. In a more recent randomized, controlled trial of
0 patients with LVEF of 35%, Toblli et al. (20) reported
hat correction of anemia (via administration of intravenous
ron) was followed by improvement in NYHA functional
lass, LVEF, and renal function. It is important to put these
ositive anemia-correction HF investigations in the per-
pective of a number of more recent negative findings.
pecifically, it should be emphasized that the results of
ulticenter trials have not always supported those of smaller
ingle-center studies (52). Ponikowski et al. (53) in a
ulticenter, randomized, double-blind, placebo-controlled
rial of 41 patients with anemia and HF failed to show any
mprovement in NYHA functional class after correction of
nemia. Similarly, in another multicenter, randomized,
lacebo-controlled study, correction of hemoglobin level did
ot change the NYHA functional class or LVEF (54).
inally, the results of the largest multicenter, double-blind,
lacebo-controlled trial (STAMINA-HeFT [Study of Ane-
ia in Heart Failure–Heart Failure Trial]) were recently
ublished (55). It included 319 patients with HF (EF
40%) with anemia (hemoglobin level of 9 to 12 g/dl). Of
he patients treated with darbepoetin alfa, 85% achieved 2
onsecutive hemoglobin levels of 14 g/dl during the study.
orrection of anemia in these patients did not significantly
mprove exercise duration, NYHA functional class, or even
ealth-related quality of life. Despite these trials with
egative findings and a paucity of data concerning mortality,
t has generally been viewed that the preponderance of
vidence supports a beneficial impact of anemia correction
n HF symptoms, LVEF, and quality of life. Not surpris-
ngly, however, there is no generally accepted consensus for
he details of treatment guidelines, protocols, or hemoglo-
in target levels in patients with HF.
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Anemia in CKD and HF February 24, 2009:639–47nemia Correction: Different
utcomes for CKD Versus HF?
he apparent disparate impact of anemia correction for
KD versus HF in some trials emphasizes our limited
nderstanding of the bidirectional relationships in the triad
f the cardiorenal anemia syndrome. In other words, the fact
hat these conditions coexist in a large number of patients,
hat they can cause and worsen each other, and that they
ave an additive effect on increasing mortality does not
ecessarily mean that the pathophysiologic basis of their
inkage would be the same. For example, although severe
nemia seems to be a “mediator” for worse outcomes in both
atients with HF and patients with renal failure, milder
egrees could be a partial “defense mechanism” in patients
ith parenchymal CKD. Indeed, in experimental models of
KD, chronic moderate anemia reduced glomerular injury,
hereas raising hemoglobin values by use of EPO resulted
n accelerated glomerulosclerosis (56,57). If this hypothesis
s true, it is conceivable that overly aggressive correction of
nemia in patients with CKD can result in abrogation of
uch a defense mechanism with a subsequent increase in the
ate of adverse outcomes. This concept would thereby
upport the use of a narrow therapeutic hemoglobin window
n renal disease-specific erythropoietic guidelines.
Another possible explanation for this apparent divergence
ould be the fact that in most of these studies, the
ntervention was limited to the administration of ESAs
ither in the form of EPO (50) or the longer-acting analog
darbepoetin alfa) (21,58). Anemia correction is not neces-
arily synonymous to administration of ESAs. Indeed, a few
tudies have chosen to use other interventions (e.g., intra-
enous iron alone or a combination of iron and ESAs) to
orrect anemia in the HF population (19–22). Similarly,
ontinuous EPO receptor activator, with a unique pharma-
ologic profile including a longer elimination half-life and
lower clearance rate, has recently been developed for
orrection of anemia in patients with CKD (59) and has
een used in patients with and without ESRD (60,61).
herefore, upon reviewing these studies, it needs to be kept
n mind that the results (positive or negative) might be due
o other drug-related effects, rather than the impact of
nemia correction per se. This concept is further reinforced
y recent findings on the physiologic effects of EPO that go
ar beyond erythropoiesis (e.g., reduction in apoptosis and
timulation of endothelial progenitor cell proliferation)
19,42,62). One can then postulate that besides their role in
rythropoiesis and correction of anemia, ESAs could exert
xtrahematopoietic effects that are different in the heart and
he kidney, explaining the discrepancies in the findings of
he aforementioned clinical studies.
The nephrology and cardiology literature showing that
nemia correction yielded disparate outcomes in the CKD
nd HF populations might also be in part due to differences
n study design. The large-scale trials in patients with CKD
ere specifically structured to assess either a composite of weveral cardiovascular events (45,46) or the length of time to
eath or first nonfatal myocardial infarction as their primary
nd points (47). The mean duration of observation for the
rimary end point in patients in the CREATE study was
lmost 3 years; the median follow-up period was 16 months
or patients in the CHOIR study and 14 months for those
n the normal hematocrit study (45–47). The investigations
ere specifically powered to detect the differences in adverse
utcomes during these follow-up periods. This approach
eeds to be cautiously compared with those from studies on
nemia correction in patients with HF, which have gener-
lly included smaller number of patients with shorter
urations of follow-up. Furthermore, the primary end
oints in these cardiology trials have mostly been improve-
ent in exercise tolerance, NYHA functional class, LVEF,
nd health-related quality of life (efficacy rather than safety)
51,58). The fact that they did not detect any increase in
dverse outcomes (unlike the CKD investigations) might
hus partially be due to their being underpowered and
aving short follow-up periods. The need to more rigor-
usly evaluate the safety of anemia correction in the HF
opulation has been well recognized, and a large-scale,
ouble-blind, randomized phase 3 morbidity and mortality
rial (RED-HF [Reduction of Events with Darbepoetin
lfa in Heart Failure]) is currently ongoing to specifically
etermine anemia correction’s impact on the morbidity and
ortality of these patients (63).
he Target Hemoglobin Level
or Patients With Both CKD and HF
oncerning the treatment of anemia in patients who
resent with cardiorenal anemia syndrome, the main unre-
olved issue is determining the safest hemoglobin level to
arget with pharmacologic therapy (64). Although there is
o clear-cut answer to this question yet, there are some
lues. Regarding the cardiac constituent of the syndrome,
e simply do not know definitively what the impact of
nemia correction or normalization would be on the mor-
ality and morbidity of the HF population. As noted earlier,
ven in terms of its effect on exercise tolerance, symptoms,
nd quality of life, the current data are controversial.
herefore, it seems reasonable to look at the renal compo-
ent of the syndrome for which there are large-scale,
andomized trials specifically designed to answer this ques-
ion (45–47). Because HF and CKD coexist in a large
umber of patients, even if these studies were designed and
ntended for the CKD population, they have invariably
ncluded significant number of patients with coexisting HF;
t was present in 32% of patients in the CREATE study and
3% of those in the CHOIR study. Although no subgroup
nalysis is currently available for these studies to assess
hether patients presenting with concurrent CKD and HF
ollowed the general pattern found in the study population
s a whole, in the absence of any conflicting data, there
ould be no reason to assume that this subgroup of patients
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hen we can identify individuals who have reversible
emodynamic renal dysfunction (and who theoretically
enefit from HF rather than renal hemoglobin guidelines),
t seems reasonable to suggest that correction of anemia in
atients with cardiorenal anemia syndrome be based on
uidelines for patients with only CKD (48). The problem
ith this pragmatic approach of using the relatively modest
renal” hemoglobin targets (i.e., 10 to 12 g/dl) is that based
n some cardiology trials, there are substantial numbers of
atients who might benefit from more aggressive anemia
orrection. In the analysis of Young et al. (11), fully a
uartile of patients were in the 12- to 13.5-g/dl group.
ilverberg et al. (36) included a subgroup with 12 to 13.5
/dl, Mancini et al. (65) described patients who reached a
4.3-g/dl hemoglobin level, Comin-Colet et al. (37) re-
orted dosing to 13.7 g/dl, and Felker et al. (66) described
hose with hemoglobin values of 13.9%. Importantly,
olden et al. (67) described the better outcomes with
ematocrits 42% (well above CKD guidelines) compared
ith values 35%. Similarly, there were reported benefits
rom hemoglobin levels of 14 to 14.9 g/dl, rather than
10.9 g/dl (68), as well as the lowest mortality for patients
HF with Normal Renal Function, 
or Stages 1-4 CKD
At Research Protocol 
Goal Based on GFR, 
Hgb 12-14.5 g/dl
Re-assess GFR
Hgb < Go
Measure Ir
At Clinical Practice 
Goal, Hgb 10-12 g/dl
Fe sat <20%
Ferritin <100
Replete ir
Stratify Patient 
By Hgb Goal
Start & 
Titrate ESA
Fe sat >20% &
Ferritin >100 ng/ml
Measure Hgb
Figure 2 Proposed Iterative Strategy for Anemia Correction in P
*Using ferritin levels as a criteria for iron depletion is controversial as they can be
chronic kidney disease; ESA  erythropoiesis-stimulating agent; ESRD  end-stag
failure; Hgb  hemoglobin concentration.ith values in the 14.5- to 15.4-g/dl range (69). Therefore,
his hemoglobin target gap between the 12 g/dl of national
KD guidelines and approximately 14 g/dl from a few HF
tudies presents a therapeutic conundrum. The “hematogap”
ffects such a large group of patients with HF that it
arrants in-depth investigation. Our opinion is that because
he adverse cardiovascular outcomes from the high-
ematocrit CKD trials were both unanticipated and severe
i.e., halting some trials), those targets should only be used
or HF in the setting of rigorous research protocols with
ngoing safety monitoring. Besides, trials need to be pow-
red to account for a subset of patients who may have such
emodynamic improvement in their renal dysfunction (i.e.,
ransitioning from CKD stage 3 back to 2) that they would
all under a different (perhaps higher) hemoglobin target
rotocol. We summarize in Figure 2 our proposed iterative
trategy for anemia correction that encompasses the concept
f how enhanced kidney function in turn alters the hemo-
lobin target; specific goals would depend on whether the
ndividual was being treated in clinical practice or using a
esearch protocol. Notably, it is anticipated that the baseline
FR for patients enrolled in the RED-HF trial will be
pproximately 53 ml/min/1.73m2 (63). This trial therefore
Stage Renal 
Function:
Assess GFR
CHF with Stage 
5 CKD (ESRD)
Hgb <10 g/dl
Measure Iron
Hgb 10-12 g/dl
At Goal, Observe
Fe sat <20%*
Replete iron
Measure Hgb
Start & 
Titrate ESA
Fe sat >20% &
Ferritin >100 ng/ml*
nts With CKD and HF
unded by inflammatory conditions. CHF  congestive heart failure; CKD 
l disease; Fe sat  iron saturation; GFR  glomerular filtration rate; HF  heartal
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Anemia in CKD and HF February 24, 2009:639–47ill hopefully provide clinicians with valuable information
n the impact of anemia correction in patients who present
ith both CKD and HF and might set new target hemo-
lobin levels for these patients.
In summary, investigations have thus far yielded impor-
ant insights into the pathophysiology of the cardiorenal
nemia syndrome and have been the basis for ESA protocols
urrently in use; however, those trials have raised a number
f unanswered questions, many of which unfortunately
evolve around the possible benefit or harm from high
emoglobin targets in patients with HF with parenchymal
s opposed to hemodynamically reversible renal dysfunction.
e have stressed the need to monitor patients for changes
n their renal function to properly categorize them and
hereby determine the appropriate disease-specific thera-
eutic hemoglobin goal. Ongoing large trials will hopefully
esolve these questions, and until such time we believe a
onservative approach to ESA protocols is warranted out-
ide of the setting of rigorously monitored protocols.
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